231 related articles for article (PubMed ID: 26618550)
1. Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party.
Robinson SP; Boumendil A; Finel H; Blaise D; Poiré X; Nicolas-Virelizier E; Or R; Malladi R; Corby A; Fornecker L; Caballero D; Pohlreich D; Nagler A; Thieblemont C; Finke J; Bachy E; Vincent L; Schroyens W; Schouten H; Dreger P
Bone Marrow Transplant; 2016 Mar; 51(3):365-71. PubMed ID: 26618550
[TBL] [Abstract][Full Text] [Related]
2. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.
Evens AM; Vanderplas A; LaCasce AS; Crosby AL; Nademanee AP; Kaminski MS; Abel GA; Millenson M; Czuczman MS; Rodriguez MA; Niland J; Zelenetz AD; Gordon LI; Friedberg JW
Cancer; 2013 Oct; 119(20):3662-71. PubMed ID: 23921646
[TBL] [Abstract][Full Text] [Related]
3. Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.
Chen YB; Li S; Fisher DC; Driscoll J; Del Rio C; Abramson J; Armand P; Barnes J; Brown J; Cutler C; El-Jawahri A; Ho VT; Hochberg E; McAfee S; Takvorian R; Spitzer TR; Antin JH; Soiffer R; Jacobsen E
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1583-8. PubMed ID: 26009261
[TBL] [Abstract][Full Text] [Related]
4. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group.
Villa D; Crump M; Panzarella T; Savage KJ; Toze CL; Stewart DA; MacDonald DA; Buckstein R; Lee C; Alzahrani M; Rubinger M; Foley R; Xenocostas A; Sabloff M; Muccilli A; Chua N; Couture F; Larouche JF; Cohen S; Connors JM; Ambler K; Al-Tourah A; Ramadan KM; Kuruvilla J
J Clin Oncol; 2013 Mar; 31(9):1164-71. PubMed ID: 23401459
[TBL] [Abstract][Full Text] [Related]
5. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).
Dietrich S; Boumendil A; Finel H; Avivi I; Volin L; Cornelissen J; Jarosinska RJ; Schmid C; Finke J; Stevens WB; Schouten HC; Kaufmann M; Sebban C; Trneny M; Kobbe G; Fornecker LM; Schetelig J; Kanfer E; Heinicke T; Pfreundschuh M; Diez-Martin JL; Bordessoule D; Robinson S; Dreger P
Ann Oncol; 2014 May; 25(5):1053-8. PubMed ID: 24585719
[TBL] [Abstract][Full Text] [Related]
6. R-BEAM versus Reduced-Intensity Conditioning Regimens in Patients Undergoing Allogeneic Stem Cell Transplantation for Relapsed Refractory Diffuse Large B Cell Lymphoma.
Modi D; Kim S; Surapaneni M; Ayash L; Alavi A; Ratanatharathorn V; Deol A; Uberti JP
Biol Blood Marrow Transplant; 2020 Apr; 26(4):683-690. PubMed ID: 31682979
[TBL] [Abstract][Full Text] [Related]
7. Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma-a long-term follow-up single center experience.
Roerden M; Sökler M; Kanz L; Bethge W; Vogel W; Walz JS
Ann Hematol; 2020 Feb; 99(2):265-276. PubMed ID: 31897675
[TBL] [Abstract][Full Text] [Related]
8. Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant.
Khouri IF; Milton DR; Gulbis AM; Jabbour EJ; Nastoupil L; Ledesma C; Anderlini P; Bashir Q; Daher M; Im JS; Iyer SP; Marin D; Mehta RS; Olson AL; Popat UR; Qazilbash M; Saini N; Samaniego F; Rondon G; Medeiros LJ; Champlin RE
Clin Cancer Res; 2021 Nov; 27(21):5847-5856. PubMed ID: 34380640
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect.
Dodero A; Spina F; Narni F; Patriarca F; Cavattoni I; Benedetti F; Ciceri F; Baronciani D; Scimè R; Pogliani E; Rambaldi A; Bonifazi F; Dalto S; Bruno B; Corradini P
Leukemia; 2012 Mar; 26(3):520-6. PubMed ID: 21904377
[TBL] [Abstract][Full Text] [Related]
10. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.
Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI;
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879
[TBL] [Abstract][Full Text] [Related]
11. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Sirvent A; Dhedin N; Michallet M; Mounier N; Faucher C; Yakoub-Agha I; Mohty M; Robin M; Tabrizi R; Clement L; Bilger K; Larosa F; Contentin N; Huyn A; François S; Bulabois CE; Ceballos P; Bourrhis JH; Buzyn A; Cornillon J; Guillerm G; de Revel T; Bay JO; Guilhot F; Milpied N
Biol Blood Marrow Transplant; 2010 Jan; 16(1):78-85. PubMed ID: 19744569
[TBL] [Abstract][Full Text] [Related]
12. Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT†.
Robinson SP; Boumendil A; Finel H; Schouten H; Ehninger G; Maertens J; Crawley C; Rambaldi A; Russell N; Anders W; Blaise D; Yakoub-Agha I; Ganser A; Castagna L; Volin L; Cahn JY; Montoto S; Dreger P
Ann Oncol; 2016 Jun; 27(6):1088-1094. PubMed ID: 26961149
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era.
Nagle SJ; Woo K; Schuster SJ; Nasta SD; Stadtmauer E; Mick R; Svoboda J
Am J Hematol; 2013 Oct; 88(10):890-4. PubMed ID: 23813874
[TBL] [Abstract][Full Text] [Related]
14. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation.
Cwynarski K; van Biezen A; de Wreede L; Stilgenbauer S; Bunjes D; Metzner B; Koza V; Mohty M; Remes K; Russell N; Nagler A; Scholten M; de Witte T; Sureda A; Dreger P
J Clin Oncol; 2012 Jun; 30(18):2211-7. PubMed ID: 22547610
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic stem cell transplantation for mantle cell lymphoma-update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74).
Krüger WH; Hirt C; Basara N; Sayer HG; Behre G; Fischer T; Grobe N; Maschmeyer G; Neumann T; Schneidewind L; Niederwieser D; Dölken G; Schmidt CA
Ann Hematol; 2021 Jun; 100(6):1569-1577. PubMed ID: 33829299
[TBL] [Abstract][Full Text] [Related]
16. The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma.
Robinson S; Dreger P; Caballero D; Corradini P; Geisler C; Ghielmini M; Le Gouill S; Kimby E; Rule S; Vitolo U; Dreyling M; Hermine O;
Leukemia; 2015 Feb; 29(2):464-73. PubMed ID: 25034148
[TBL] [Abstract][Full Text] [Related]
17. A prospective phase II study of RICE re-induction, then high-dose fludarabine and busulfan, followed by autologous or allogeneic blood stem cell transplantation for indolent b-cell lymphoma.
Stewart DA; Duan Q; Carlson L; Russell JA; Bahlis NJ; Duggan P; Hasegawa W; Voralia M
Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):475-82. PubMed ID: 21831743
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study.
Rigacci L; Puccini B; Dodero A; Iacopino P; Castagna L; Bramanti S; Ciceri F; Fanin R; Rambaldi A; Falda M; Milone G; Guidi S; Martelli MF; Mazza P; Oneto R; Bosi A;
Ann Hematol; 2012 Jun; 91(6):931-9. PubMed ID: 22245922
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.
Chamoun K; Milton DR; Ledesma C; Young KH; Jabbour EJ; Alatrash G; Anderlini P; Bashir Q; Ciurea SO; Marin D; Molldrem JJ; Olson AL; Oran B; Popat UR; Rondon G; Champlin RE; Gulbis AM; Khouri IF
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1347-1354. PubMed ID: 30826465
[TBL] [Abstract][Full Text] [Related]
20. Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease.
Beitinjaneh A; Saliba RM; Medeiros LJ; Turturro F; Rondon G; Korbling M; Fayad L; Fanale MA; Alousi AM; Anderlini P; Betul O; Popat UR; Pro B; Khouri IF
Biol Blood Marrow Transplant; 2015 May; 21(5):855-9. PubMed ID: 25652691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
